It is quite interesting. I was much more animated about the contract a while back but I have read a number of articles, even as recently as this week, where I read 2 articles about pharmaceutical companies being in arrangements where they receive a longer term royalty after selling the rights to a drug. One of them was a post on HC about a drug that Pfizer still took a cut of after selling/licensing it.
It seems like its not an uncommon practice and did not stop future acquisition or significantly impact its prospects.
I think some certainty in any arrangements with Acadia would be beneficial - in terms of a possible cut they may receive for future conditions that are on their radar etc.
It is quite interesting. I was much more animated about the...
-
- There are more pages in this discussion • 132 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.61 |
Change
0.280(2.10%) |
Mkt cap ! $1.739B | |||
| Open | High | Low | Value | Volume |
| $13.49 | $13.64 | $13.30 | $4.821M | 356.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3602 | $13.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.66 | 1655 | 2 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |